electrophysiology procedures News
-
Cardiva Medical Announces First Patients Enrolled in The AMBULATE Same Day Discharge Study Using VASCADE MVP
SANTA CLARA, Calif., July 16, 2020 -- Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the first patient enrollments in its AMBULATE Same Day Discharge study, the first prospective multi-center study designed to evaluate same-day discharge for patients undergoing cardiac ablation procedures for atrial fibrillation. The study is utilizing the VASCADE MVP Venous ...
-
Cardiva Medical Announces FDA Approval of the VASCADE MVP Vascular Closure System for Multi-Site Vessel Closure Following Electrophysiology Procedures
VASCADE MVP is the first vessel closure technology designed for electrophysiology procedures – and proven by electrophysiology physicians in a multi-center, randomized, controlled clinical trial. Potential procedures include cardiac ablation and left atrial appendage closure among others. Greater than 400,000 patients per year in the United States may benefit – with procedures ...
-
Cardiva Medical Announces $45 Million Financing Led by EW Healthcare Partners
SANTA CLARA, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Cardiva Medical, Inc, an innovator in the field of vascular closure, today announced the completion of a $45 million equity financing round. The equity round included new investor EW Healthcare Partners in addition to Cardiva Medical’s existing major investors, including affiliates of Luther King Capital Management, PTV Healthcare ...
-
Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical Electrophysiology
Santa Clara, Calif. - October 30, 2019 - Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced that positive results from the AMBULATE pivotal study demonstrating the safety and efficacy of the company’s VASCADE® MVP Venous Vascular Closure System compared to manual compression were published online in the Journal of the American College of Cardiology: ...
-
Cardiva Medical Announces Positive Results of the AMBULATE Pivotal Study Evaluating the VASCADE MVP System Compared to Manual Compression for Multi-Vessel Closure Following Electrophysiology Procedures
The AMBULATE pivotal study met its primary efficacy endpoint. The median time to patients getting on their feet following arrhythmia ablation procedures was reduced by 3.9 hours. AMBULATE demonstrated that patients in the VASCADE MVP arm had significantly improved patient satisfaction and a significant reduction in the post-procedure use of opioid pain medications. Late-breaking results were ...
-
First Patients in the U.S. Enrolled in Biosense Webster Clinical Study To Evaluate VARIPULSE™ Catheter for Atrial Fibrillation
Johnson & Johnson MedTech* announced today that Biosense Webster, Inc., a worldwide leader in the science and technology of cardiac arrhythmia treatment, enrolled the first patients in its admIRE clinical study in the United States. admIRE is a prospective, multi-center, non-randomized study that will enroll more than 400 patients in the U.S. to evaluate the safety and effectiveness of ...
-
Imricor Announces Development Agreement with MIPM
Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in Realtime iCMR cardiac ablation products, is pleased to announce it has entered into a Development Agreement with Mammendorfer Institut für Physik und Medizin GmbH (MIPM), a leading developer and manufacturer of MRI-compatible medical devices, including an MRI-compatible external cardioverter defibrillator. MIPM ...
By Imricor
-
Acutus Medical Initiates CE Mark Study for Focal Pulsed Field Ablation Therapy to Treat Atrial Fibrillation
Acutus Medical, Inc. (Nasdaq: AFIB) (“Acutus”), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the initiation of AcQForce PFA-CE, a new clinical study that will evaluate the safety and performance of the company’s focal force sensing Pulsed Field Ablation (PFA) catheter and system in combination with ...
-
AtriCure’s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients
Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for long-standing persistent Afib patients. Study also showed improved Electrophysiology Lab efficiency AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced U.S. Food and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you